Related Experiment Video
Updated: May 10, 2026

Non-invasive Optical Measurement of Cerebral Metabolism and Hemodynamics in Infants
Published on: March 14, 2013
Biochemical signs of impaired cobalamin function do not affect hematological parameters in young infants: results
Håvard Bjørke Jenssen1, Ingrid Torsvik, Per Magne Ueland
1Royal College of Surgeons in Ireland, Dublin, Ireland.
Insights
Cobalamin supplementation did not improve infant blood cell counts, even with biochemical signs of deficiency. Iron status, not cobalamin, was the main factor influencing erythrocyte parameters in infants.
Area of Science:
- Pediatric Hematology
- Nutritional Biochemistry
- Developmental Pediatrics
Background:
- Cobalamin (vitamin B12) deficiency in infants can cause developmental delay and anemia, though macrocytic anemia is rare and linked to severe deficiency.
- Iron deficiency is the primary cause of anemia in infants.
- This study investigated infants with biochemical evidence of impaired cobalamin function.
Purpose of the Study:
- To assess the impact of cobalamin supplementation on hematological parameters in infants with biochemical signs of impaired cobalamin function.
- To determine the relationship between cobalamin status and iron status in infant erythropoiesis.
Main Methods:
- A randomized controlled trial involving 107 infants at 6 weeks of age.
- Infants received either an intramuscular cobalamin injection (400 μg) or no intervention.
- Hematological parameters, cobalamin, and folate levels were measured at baseline and 4 months.
Main Results:
- Cobalamin supplementation improved markers of cobalamin function but did not affect hematological cell counts at 4 months.
- Signs of iron-restricted erythropoiesis were present at both 6 weeks and 4 months.
- Male gender and higher weight gain percentage were predictors of low iron status at 4 months.
Conclusions:
- Cobalamin supplementation does not enhance hematological cell counts in infants with biochemical signs of impaired cobalamin function.
- Erythrocyte parameter variations in this age group are primarily linked to iron status rather than cobalamin levels.
Background:
Whereas iron deficiency is considered the leading cause of anemia in infants, cobalamin deficiency is foremost characterized by developmental delay, and the typical macrocytic anemia is confined to severe and longstanding cobalamin deficiency in this age group. Hematological parameters were investigated in 4-mo-old infants with biochemical signs of impaired cobalamin function who participated in a randomized controlled cobalamin intervention study at 6 wk.
Methods:
One hundred and seven infants were randomly assigned to receive either an intramuscular injection with 400 μg cobalamin or no intervention at 6 wk. Hematological parameters, and cobalamin and folate status were determined at inclusion and 4 mo.
Results:
Cobalamin supplementation improved all markers of impaired cobalamin function but had no effect on hematological cell counts at 4 mo (P > 0.18). Signs indicative of an iron-restricted erythropoiesis were observed at 6 wk and 4 mo. At 4 mo, the strongest predictors of low iron status were male gender and a high percentage weight increase from birth.
Conclusion:
In infants with biochemical signs of impaired cobalamin function, supplementation does not improve hematological cell counts. Variations in erythrocyte parameters seem to be foremost associated with iron status in this age group.
Related Concept Videos
Vitamins
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Bioavailability Study Design: Healthy Subjects Versus Patients
Inborn Errors of Metabolism
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

